EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing
Recruiting · NCT06105801 · Interventional (participants receive a specific treatment) · Lead sponsor: Vanderbilt-Ingram Cancer Center
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This is a multi-center clinical trial evaluating the effect of transbronchial mediastinal cryobiopsy for its ability to improve the likelihood of obtaining tissue sufficient for molecular analysis. Patients in outpatient clinics or pre-operative holding areas planning to undergo a bronchoscopic biopsy of a suspected malignant lesion (peripheral or mediastinal) for initial diagnosis, staging, or tissue acquisition for molecular analysis will be considered for enrollment and consented. Patients will only be enrolled if intraoperative ROSE suggests malignancy. Patients will be randomized to continue with the operator's initial EBUS-TBNA needle or switch to a cryoprobe to perform a sampling.
Who can take part
Inclusion criteria
- Lesions on PET or CT concerning for primary or metastatic malignancy that are amenable to biopsy by linear EBUS
- Malignant cells present on rapid on-site cytological evaluation (ROSE)
Exclusion criteria
- Patient is known to be less than 18 years old
- Patient is known to be pregnant
- Patient is known to be a prisoner
- Operator deems lesion is not safe to biopsy
Where it is running
1 location listed across 1 US state.
- Vanderbilt University/Ingram Cancer Center - Nashville, Tennessee, United States